US EditionOzempic, Wegovy could reverse severe liver disease, study suggests
- A global phase 3 study, recently featured in a leading medical journal, demonstrated that semaglutide effectively decreases liver fat and inflammation in individuals suffering from metabolic dysfunction-associated steatohepatitis .
- The study involved 800 mostly obese patients with moderate to advanced liver scarring and about half had type 2 diabetes, who received weekly semaglutide or placebo injections over 72 weeks to evaluate liver improvements.
- Among those receiving semaglutide, 62.9% experienced significant decreases in liver fat and inflammation without worsening scarring, compared to 34.3% in the placebo group. Additionally, fibrosis improvement was observed in 36.8% of the semaglutide group versus 22.4% of participants on placebo, alongside an average weight loss of 10.5%, compared to 2% in the placebo cohort.
- The study’s lead researcher from Virginia Commonwealth University emphasized that weight loss played a significant role in the trial’s outcomes, and semaglutide’s effects on metabolism might also contribute to slowing the progression of liver disease and associated health issues.
- If approved by the FDA, semaglutide could provide a vital new treatment option for millions with MASH, a disease with limited therapies, potentially addressing both liver damage and underlying metabolic dysfunction.
Insights by Ground AI
Does this summary seem wrong?
18 Articles
18 Articles
All
Left
3
Center
5
Right
3
To sow a seed of doubt: Liver damage from natural products
By Hayden Stutz, Student Pharmacist and Karen L. Kier, Pharmacist On behalf of ONU Healthwise Pharmacy To sow a seed of doubt means to cause someone to have doubts, worries, or concerns. The sower of the seed conveys that someone is planting information into your head, creating doubt. A recent study may be planting a seed!Section: Health
Semaglutide found to have shocking benefit for liver disease patients in new study
Breakthrough research shows semaglutide effectively reverses life-threatening liver disease MASH, demonstrating significant inflammation reduction in 62.9% of clinical trial participants.
·New York, United States
Read Full ArticleCoverage Details
Total News Sources18
Leaning Left3Leaning Right3Center5Last UpdatedBias Distribution45% Center
Bias Distribution
- 45% of the sources are Center
45% Center
L 27%
C 45%
R 27%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
